Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Endometrioid | 2 | 2020 | 271 | 0.710 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2020 | 324 | 0.620 |
Why?
|
| Hysterectomy | 3 | 2019 | 927 | 0.600 |
Why?
|
| Carcinoma in Situ | 1 | 2020 | 805 | 0.500 |
Why?
|
| Fallopian Tubes | 2 | 2020 | 182 | 0.480 |
Why?
|
| Precancerous Conditions | 1 | 2020 | 975 | 0.460 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 495 | 0.460 |
Why?
|
| Metrorrhagia | 1 | 2012 | 18 | 0.440 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2012 | 102 | 0.410 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 789 | 0.390 |
Why?
|
| Laparoscopy | 5 | 2019 | 2149 | 0.380 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2013 | 2019 | 0.370 |
Why?
|
| Indoles | 2 | 2016 | 1838 | 0.340 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 387 | 0.340 |
Why?
|
| Cervix Uteri | 1 | 2013 | 590 | 0.330 |
Why?
|
| Uterine Neoplasms | 3 | 2012 | 1513 | 0.320 |
Why?
|
| Genital Neoplasms, Female | 3 | 2019 | 522 | 0.310 |
Why?
|
| Ovarian Neoplasms | 5 | 2019 | 4837 | 0.300 |
Why?
|
| Endometriosis | 1 | 2013 | 839 | 0.260 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 1255 | 0.260 |
Why?
|
| Urogenital Abnormalities | 1 | 2008 | 261 | 0.250 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2019 | 336 | 0.220 |
Why?
|
| Endometrial Neoplasms | 3 | 2020 | 1353 | 0.190 |
Why?
|
| PAX2 Transcription Factor | 1 | 2020 | 80 | 0.190 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2013 | 221 | 0.180 |
Why?
|
| Meigs Syndrome | 1 | 2019 | 6 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 4033 | 0.140 |
Why?
|
| Financing, Personal | 1 | 2019 | 308 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 13668 | 0.130 |
Why?
|
| beta Catenin | 1 | 2020 | 1059 | 0.130 |
Why?
|
| Postmenopause | 2 | 2013 | 2461 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 12961 | 0.120 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 11007 | 0.110 |
Why?
|
| Dactinomycin | 1 | 2012 | 317 | 0.110 |
Why?
|
| Colposcopy | 1 | 2013 | 144 | 0.110 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2013 | 302 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 11493 | 0.100 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1877 | 0.100 |
Why?
|
| Polyps | 1 | 2012 | 189 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2016 | 2716 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 1372 | 0.100 |
Why?
|
| Vincristine | 1 | 2012 | 1036 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2016 | 1914 | 0.090 |
Why?
|
| Gastrostomy | 1 | 2013 | 309 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 2948 | 0.090 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 221 | 0.090 |
Why?
|
| Vaginal Smears | 1 | 2013 | 511 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2012 | 3474 | 0.090 |
Why?
|
| Lymph Node Excision | 2 | 2012 | 1256 | 0.090 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 199 | 0.090 |
Why?
|
| Premenopause | 1 | 2013 | 1033 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2019 | 1859 | 0.090 |
Why?
|
| Female | 23 | 2020 | 380197 | 0.090 |
Why?
|
| Intestinal Obstruction | 1 | 2013 | 424 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3557 | 0.080 |
Why?
|
| Choriocarcinoma | 1 | 2008 | 123 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 2236 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2012 | 783 | 0.070 |
Why?
|
| Organogenesis | 1 | 2008 | 222 | 0.070 |
Why?
|
| Vasodilation | 4 | 2004 | 944 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2008 | 363 | 0.070 |
Why?
|
| Cell Survival | 1 | 2016 | 5881 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2019 | 2348 | 0.070 |
Why?
|
| Pelvic Pain | 1 | 2008 | 274 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3023 | 0.060 |
Why?
|
| Middle Aged | 13 | 2020 | 213367 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 3614 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 4929 | 0.060 |
Why?
|
| Humans | 23 | 2020 | 744220 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1376 | 0.050 |
Why?
|
| Endothelins | 1 | 2002 | 138 | 0.050 |
Why?
|
| Endothelium, Vascular | 3 | 2004 | 4455 | 0.050 |
Why?
|
| Heptanoic Acids | 1 | 2004 | 343 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2011 | 2246 | 0.050 |
Why?
|
| Vasomotor System | 1 | 2002 | 209 | 0.050 |
Why?
|
| Maleimides | 1 | 2002 | 112 | 0.050 |
Why?
|
| Endothelin-1 | 1 | 2003 | 314 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 1587 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2004 | 639 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2016 | 10480 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 16687 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2003 | 650 | 0.040 |
Why?
|
| Tyrosine | 1 | 2004 | 1461 | 0.040 |
Why?
|
| Pulmonary Circulation | 1 | 2002 | 739 | 0.040 |
Why?
|
| Survival Rate | 1 | 2013 | 12781 | 0.040 |
Why?
|
| Adult | 12 | 2019 | 214035 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 2158 | 0.040 |
Why?
|
| Vitamin E | 1 | 2003 | 869 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 3086 | 0.040 |
Why?
|
| Adnexal Diseases | 1 | 2019 | 102 | 0.040 |
Why?
|
| Palliative Care | 1 | 2013 | 3490 | 0.040 |
Why?
|
| Pyrroles | 1 | 2004 | 1143 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 18027 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2002 | 1726 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2002 | 1227 | 0.040 |
Why?
|
| CA-125 Antigen | 1 | 2019 | 286 | 0.040 |
Why?
|
| Aged | 7 | 2020 | 163253 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2009 | 1670 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2003 | 1151 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 7281 | 0.030 |
Why?
|
| Antioxidants | 1 | 2003 | 1663 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2019 | 77426 | 0.030 |
Why?
|
| Cholesterol | 1 | 2004 | 2911 | 0.030 |
Why?
|
| Pregnancy | 2 | 2013 | 29142 | 0.030 |
Why?
|
| Medical Records | 1 | 2019 | 1413 | 0.030 |
Why?
|
| Receptor, Endothelin A | 2 | 2003 | 58 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2002 | 1372 | 0.030 |
Why?
|
| Mice | 2 | 2016 | 81178 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3800 | 0.020 |
Why?
|
| Peptides, Cyclic | 2 | 2003 | 401 | 0.020 |
Why?
|
| Smoking | 2 | 2004 | 8986 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 8628 | 0.020 |
Why?
|
| Forearm | 2 | 2003 | 409 | 0.020 |
Why?
|
| Income | 1 | 2019 | 1913 | 0.020 |
Why?
|
| Vascular Resistance | 2 | 2003 | 937 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2013 | 10250 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 3256 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2019 | 2266 | 0.020 |
Why?
|
| Laparotomy | 1 | 2011 | 473 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 3336 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 25043 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 2576 | 0.020 |
Why?
|
| Self Report | 1 | 2019 | 3558 | 0.020 |
Why?
|
| Cross-Over Studies | 2 | 2004 | 2032 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 661 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 2886 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2011 | 603 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 2085 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 774 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2019 | 2494 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 1770 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 168788 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2011 | 571 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2013 | 57768 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 1184 | 0.020 |
Why?
|
| Ovary | 1 | 2011 | 981 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 3842 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 35423 | 0.020 |
Why?
|
| Young Adult | 2 | 2008 | 56436 | 0.020 |
Why?
|
| Adolescent | 1 | 2013 | 85759 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 3508 | 0.020 |
Why?
|
| Time Factors | 2 | 2019 | 40063 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 13096 | 0.010 |
Why?
|
| Robotics | 1 | 2011 | 899 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14726 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 8480 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2011 | 1076 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2011 | 2263 | 0.010 |
Why?
|
| Receptors, Endothelin | 1 | 2002 | 58 | 0.010 |
Why?
|
| Brachial Artery | 1 | 2004 | 370 | 0.010 |
Why?
|
| Oxidative Stress | 2 | 2004 | 3085 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 2382 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 2002 | 233 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2009 | 1167 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2004 | 689 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 916 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 2942 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2011 | 4026 | 0.010 |
Why?
|
| Child | 1 | 2008 | 77679 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2011 | 3469 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 1525 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2003 | 11732 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12244 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 2004 | 12035 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 1092 | 0.010 |
Why?
|
| Peptides | 1 | 2011 | 4407 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2002 | 1423 | 0.010 |
Why?
|
| Logistic Models | 1 | 2013 | 13409 | 0.010 |
Why?
|
| Length of Stay | 1 | 2011 | 6308 | 0.010 |
Why?
|
| Stem Cells | 1 | 2011 | 3567 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39045 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 3913 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 4982 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 10387 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 12718 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 9230 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2002 | 4199 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 7148 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 29050 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 21752 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 5982 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 4363 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15294 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 8343 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 10949 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 13036 | 0.010 |
Why?
|
| Male | 5 | 2004 | 350027 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2011 | 23404 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2013 | 63119 | 0.000 |
Why?
|
| Risk Factors | 1 | 2003 | 72280 | 0.000 |
Why?
|
Concepts
(190)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(24)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_